Comparative efficacy of adjuvant FOLFOX vs. FLOT following neoadjuvant FLOT in patients with locally advanced gastric cancer
Turkish Journal of Medical Sciences · 20.06.2025 · 55 (3) · 547-558
DOI: 10.55730/1300-0144.6002 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Turkish Journal of Medical Sciences, online erschienen am 20.06.2025. Verfasst von Furkan Ceylan und 13 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, University of Health Sciences, Ankara Bilkent City Hospital, Anka…. Hauptthemen laut MEDLINE: Stomach Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Neoadjuvant Therapy. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/aim: Perioperative FLOT is considered the gold standard treatment for locally advanced gastric cancer. However, in the adjuvant setting, chemotherapy intolerance has brought de-escalation strategies to the forefront as an important area of research. This study aimed to compare the efficacy of adjuvant FLOT and FOLFOX regimens in enhancing survival outcomes in patients with locally advanced gastric cancer who underwent surgical resection following neoadjuvant FLOT treatment. Materials and methods: Patients with locally advanced gastric cancer (cT2-4, N0-3) who received four cycles of neoadjuvant FLOT and subsequently underwent surgery at Ankara Bilkent City Hospital between January 2018 and September 2024 were retrospectively evaluated. Disease-free survival (DFS) and overall survival (OS) outcomes were compared to patients receiving adjuvant FOLFOX or FLOT. Clinical variables such as disease stage and response to neoadjuvant therapy were also analyzed to determine their impact on DFS and OS.
Results
The analysis included 171 patients, with a median age of 59 years and a median follow-up duration of 16.1 months. At 16 months, the DFS and OS rates were 66% and 82%, respectively. Of the 171 patients, 105 received adjuvant FLOT, 37 received FOLFOX, and 29 received no adjuvant therapy. Statistical analysis revealed no significant differences in DFS (HR: 0.63, 95% CI: 0.30–1.33, p = 0.229) or OS (HR: 0.76, 95% CI: 0.24–2.37, p = 0.635) between the FLOT and FOLFOX groups. However, the advanced disease stage and lack of pathological response to neoadjuvant FLOT were associated with decreased DFS and OS, highlighting these factors as potential prognostic indicators.
Conclusion
Among patients undergoing surgery after neoadjuvant FLOT, adjuvant FOLFOX showed comparable efficacy to FLOT, suggesting its potential as an alternative option, particularly for patients with deteriorated ECOG PS or those who developed chemotherapy intolerance postoperatively. These findings inform treatment strategies and optimize adjuvant therapy selection based on individual patient profiles.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, University of Health Sciences, Ankara Bilkent City Hospital, Ankara, Turkiye.
- Division of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Yıldırım Beyazıt University, Ankara, Turkiye.
- Faculty of Medicine, Hacettepe University, Ankara, Turkiye.
- Division of Pulmonology, Department of Internal Medicine, Faculty of Medicine, University of Health Sciences, Ankara Bilkent City Hospital, Ankara, Turkiye.
- Department of Pathology, Faculty of Medicine, University of Health Sciences, Ankara Bilkent City Hospital, Ankara, Turkiye.
ORCID-Profile: Furkan Ceylan, Didem Şener Dede, Safa Can Efil, Ateş Kutay Tenekeci, Eren Göktuğ Ceylan, Serhat Sekmek, Mehmet Çakmak, Burak Bilgin, Şebnem Yücel, Hayriye Tatli Doğan, Mehmet Ali Nahit Şendur, Muhammed Bülent Akinci, Doğan Uncu, Bülent Yalçin
Zitieren
APA
Ceylan, F., Şener Dede, D., Efil, S. C., Tenekeci, A. K., Ceylan, E. G., Sekmek, S., Çakmak, M., Bilgin, B., Yücel, Ş., Tatli Doğan, H., Şendur, M. A. N., Akinci, M. B., Uncu, D., & Yalçin, B. (2025). Comparative efficacy of adjuvant FOLFOX vs. FLOT following neoadjuvant FLOT in patients with locally advanced gastric cancer. Turkish Journal of Medical Sciences, 55(3), 547-558. https://doi.org/10.55730/1300-0144.6002
Vancouver
Ceylan F, Şener Dede D, Efil SC, Tenekeci AK, Ceylan EG, Sekmek S, et al. Comparative efficacy of adjuvant FOLFOX vs. FLOT following neoadjuvant FLOT in patients with locally advanced gastric cancer. Turkish Journal of Medical Sciences. 2025;55(3):547-558. doi:10.55730/1300-0144.6002
BibTeX
@article{Ceylan2025,
author = {Ceylan, Furkan and Şener Dede, Didem and Efil, Safa Can and Tenekeci, Ateş Kutay and Ceylan, Eren Göktuğ and Sekmek, Serhat and Çakmak, Mehmet and Bilgin, Burak and Yücel, Şebnem and Tatli Doğan, Hayriye and Şendur, Mehmet Ali Nahit and Akinci, Muhammed Bülent and Uncu, Doğan and Yalçin, Bülent},
title = {Comparative efficacy of adjuvant FOLFOX vs. FLOT following neoadjuvant FLOT in patients with locally advanced gastric cancer},
journal = {Turkish Journal of Medical Sciences},
year = {2025},
volume = {55},
number = {3},
pages = {547--558},
doi = {10.55730/1300-0144.6002}
}
EUVIMED